A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses

References

• Corman VM, Muth D, Niemeyer D, et al. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163–188.
   PubMed Web of Science ®Google Scholar
• Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–154.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454.
   PubMed Web of Science ®Google Scholar
• Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiology. 2020;5:562–569.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135.
   PubMed Web of Science ®Google Scholar
• Wang P, Casner RG, Nair MS, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host & Microbe. 2021;29:747–751.
   PubMed Web of Science ®Google Scholar
• Annavajhala MK, Mohri H, Wang P, et al. Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York. Nature. 2021;597:703–708.
   PubMed Web of Science ®Google Scholar
• Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021;184:3426–3437.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584:450–456.
   PubMed Web of Science ®Google Scholar
• Wang P, Liu L, Nair MS, et al. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg Microbes Infect. 2020;9:2091–2093.
   PubMed Web of Science ®Google Scholar
• Chu H, Chan JF, Yuen TT, et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe. 2020;1:e14–e23.
   PubMedGoogle Scholar
• Suloway C, Pulokas J, Fellmann D, et al. Automated molecular microscopy: The new Leginon system. J Struct Biol. 2005;151:41–60.
   PubMed Web of Science ®Google Scholar
• Punjani A, Rubinstein JL, Fleet DJ, et al. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14:290–296.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park Y-J, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–292.
   PubMed Web of Science ®Google Scholar
• Adams PD, Gopal K, Grosse-Kunstleve RW, et al. Recent developments in the PHENIX software for automated crystallographic structure determination. J Synchrotron Radiat. 2004;11:53–55.
   PubMed Web of Science ®Google Scholar
• Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126–2132.
   PubMed Web of Science ®Google Scholar
• Davis IW, Murray LW, Richardson JS, et al. MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res. 2004;32:W615–W619.
   PubMed Web of Science ®Google Scholar
• Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007;372:774–797.
   PubMed Web of Science ®Google Scholar
• Cerutti G, Guo Y, Zhou T, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021;29:819–833. e7.
   PubMed Web of Science ®Google Scholar
• Rapp M, Guo Y, Reddem ER, et al. Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. Cell Rep. 2021;35:108950.
   PubMed Web of Science ®Google Scholar
• Cerutti G, Rapp M, Guo Y, et al. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Structure. 2021;29:655–663.
   PubMed Web of Science ®Google Scholar
• Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368:630–633.
   PubMed Web of Science ®Google Scholar
• Pinto D, Park Y-J, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290–295.
   PubMed Web of Science ®Google Scholar
• Liu H, Wu NC, Yuan M, et al. Cross-Neutralization of a SARS-CoV-2 antibody to a functionally conserved site Is mediated by avidity. Immunity. 2020;53:1272–1280.
   PubMed Web of Science ®Google Scholar
• Jette CA, Cohen AA, Gnanapragasam PNP, et al. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Rep. 2021;36:109760.
   PubMed Web of Science ®Google Scholar
• Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in manaus, Brazil. Science. 2021;372:815–821.
   PubMed Web of Science ®Google Scholar
• Naveca FG, Nascimento V, de Souza VC, et al. COVID-19 in amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. Nat Med. 2021;27:1230–1238.
   PubMed Web of Science ®Google Scholar
• Lv Z, Deng Y-Q, Ye Q, et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020;369:1505–1509.
   PubMed Web of Science ®Google Scholar
• Zhou D, Duyvesteyn HME, Chen C-P, et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol. 2020;27:950–958.
   PubMed Web of Science ®Google Scholar
• Wec AZ, Wrapp D, Herbert AS, et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. 2020;369:731–736.
   PubMed Web of Science ®Google Scholar
• Tortorici MA, Czudnochowski N, Starr TN, et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature. 2021;597:103–108.
   PubMed Web of Science ®Google Scholar
• Martinez DR, Schaefer A, Gobeil S, et al. A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice. Sci Transl Med. 2021;eabj7125. DOI: 10.1126/scitranslmed.abj7125. Online ahead of print.
   Google Scholar
• Pinto D, Sauer MM, Czudnochowski N, et al. Broad betacoronavirus neutralization by a stem helix specific human antibody. Science. 2021;373:1109–1116.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yuan M, Song G, et al. A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes. 2021. Doi: 10.1101/2021.03.30.437769. Preprint.
   Google Scholar
• Zhao F, Yuan M, Keating C, et al. Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution. 2021. DOI: 10.1101/2021.05.29.443900
   Google Scholar
• Rappazzo CG, Tse LV, Kaku CI, et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021;371:823–829.
   PubMed Web of Science ®Google Scholar